Efficacy Of Nepafenac Research Articles

Study of the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with diabetes mellitus type 2

Objective: To evaluate the effect of adding topical Nepafenac 0.1% eye drop on increasing mydriasis in patients with Diabetes Mellitus type 2. Methods: the study was conducted on 73 eyes of 73 patients who had type 2 diabetes for 5 years or more. The pupil diameter (PD) was measured in the both eyes without dilation using an Autorefractokeratometer (Grand Seiko\GR- 3500 Ka), then the pupils were dilated in the both eyes using topical Tropicamide 1%. A second measurement of (PD) was taken after dilating using the same device. Topical Nepafenac 0.1% were prescribed 3 times a day for 3 days in the right eye. During the review, after 3 days, the pupils were dilated using topical Tropicamide 1%. A third measurement of the (PD) of the both eyes was taken after dilation using the same device. The efficacy of Nepafenac 0.1% was evaluated by determining the increase in (PD) in the eye that received topical Nepafenac 0.1% and comparing it with the other eye that did not receive. Results: The mean diameter of the pupil in the right eye after dilation was 4.68±0.8 mm and in the left eye was 4.67±0.7 mm (P=0.8). After applying Nepafenac 0.1% topically 3 times a day in the right eye for 3 days, the mean diameter of the pupil in the right eye after dilation was 6.50 ± 0.9 mm and in the left eye 5.10± 0.08 mm (P=0.001). The change in the mean diameter of the pupil in the right eye was 1.82 ± 0.7 mm, and in the left eye was 0.43 ± 0.6 mm. Conclusion: Topical application of Nepafenac 0.1% showed an increase in pupillary diameter after dilation with Tropicamide 1% in patients with type 2 diabetes mellitus.

Comparison of the efficacy of nepafenac 0.1% in quiescent Behçet's uveitis and non-uveitic healthy patients after phacoemulsification surgery.

To compare the efficacy of nepafenac on anterior chamber flare and intraocular pressure(IOP) in healthy (group 1) and uveitic eyes (group 2) undergoing cataract surgery. A retrospective, consecutive case series study. Among 54 the patients, 14 had a history of uveitis. The groups were similar in age and gender. There were significant changes in flare values in both groups. When the temporal changes of flare values were compared, there was no difference between the two groups. There were no significant changes in IOP values in both group. When the temporal changes of IOP values were compared, there was no difference between the groups. Nepafenac 0.1% has been shown to be effective in suppressing inflammation after cataract surgery in uveitic eyes as well as in healthy eyes. In addition, it has been observed that it does not increase intraocular pressure in both healthy and uveitic eyes and it is safe to usewith this regard.

English

English

A comparative study on efficacy of nepafenac and flurbiprofen in maintenance of intraoperative mydriasis during cataract surgery: an open label randomized controlled trial

Background: Surgery on the ocular tissue brings about activation of phospholipase A3 thereby releasing prostaglandins and leukotrienes. Prostaglandins bring about meiosis during surgery, changes in IOP, conjunctival hyperaemia. Newer topical NSAID’s Nepafenac and Flurbiprofen are potent inhibitors of the cyclooxygenase enzyme thereby inhibiting the biosynthesis of prostaglandins. Objective of this study was to compare the efficacy of preoperative use of topical Nepafenac (0.1%) and Flurbiprofen (0.03%) in maintenance of intraoperative mydriasis during cataract surgery.Methods: A randomised, comparative study was performed on 104 patients, 52 were allocated in each group and were given either of the topical NSAID’s Nepafenac or Flurbiprofen prior to cataract surgery. Pupillary diameter was measured at the beginning and at the end of the surgery and the values were compared between the groups. Mean and standard deviation was calculated and between two groups comparison was done using students t-test.Results: The mean pupillary diameter of the two groups were comparable at the beginning of surgery (p=0.34). The mean change in the pupillary diameter was 1.86±0.71mm in the Nepafenac group and 1.77±0.72mm in the Flurbiprofen group. There was no statistically significant difference among both the groups in maintenance of intraoperative mydriasis (p=0.47).Conclusions: Pre-operative use of Nepafenac and Flurbiprofen were equally effective in preventing meiosis during cataract surgery.

Intracameral Use of Nepafenac: Safety and Efficacy Study

ABSTRACTPurpose: To test the intracameral safety of nepafenac and its efficacy in inhibiting prostaglandin synthesis during phacoemulsification surgery.Methods: The safety evaluation was conducted in normal eyes of rabbits, 0.1ml of 0.3% and 1% nepafenac was injected intracamerally. Extensive studies to detect adverse response ranged from a gross examination of eyes under slit lamp biomicroscope, fluorescein dye test, Schirmer tear test, test for corneal sensitivity, intraocular pressure measurement (IOP), specular microscopy, electroretinography(ERG), and histopathological examination of intraocular tissues. Efficacy of nepafenac was studied by intracameral injection of 0.1%, 0.3% nepafenac, nepafenac 0.3%+1% lignocaine, and 1% lignocaine alone, before phacoemulsification surgery and intraoperative mydriasis along with PGE2(ProstaglandinE2) secretion were recorded.Results: Single 0.1ml of 0.3% or 1% nepafenac did not significantly (p > 0.05) alter physiological parameters and histology of cornea, iris, and retina. Nepafenac 0.3% effectively inhibited PGE2 secretion. No significant (p > 0.05) prevention of miosis was recorded with 0.1% or 0.3% nepafenac. However, a combination of 0.3% nepafenac + 1% lignocaine and 1% lignocaine alone significantly (p < 0.05) arrested miosis during the intraoperative period.Conclusion: An intracameral concentration of up to 1% nepafenac does not adversely affect the rabbit eye. Nepafenac fails to prevent miosis but inhibits prostaglandin release during phacoemulsification surgery.

Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy

Background/aimsThis study evaluated nepafenac ophthalmic suspension 0.1% for prevention of macular oedema (MO) when used 90 days following cataract surgery in patients with diabetic retinopathy (DR).MethodsRandomised, double-masked, vehicle-controlled, parallel group...